Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Mathias, Loft"'
Autor:
Esben Andreas Carlsen, Kristian Lindholm, Amalie Hindsholm, Mathias Gæde, Claes Nøhr Ladefoged, Mathias Loft, Camilla Bardram Johnbeck, Seppo Wang Langer, Peter Oturai, Ulrich Knigge, Andreas Kjaer, Flemming Littrup Andersen
Publikováno v:
EJNMMI Research, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Background Segmentation of neuroendocrine neoplasms (NENs) in [64Cu]Cu-DOTATATE positron emission tomography makes it possible to extract quantitative measures useable for prognostication of patients. However, manual tumor segmentation is cu
Externí odkaz:
https://doaj.org/article/eeb514d8235f486b8e309f1663897bd7
[68Ga]Ga-NODAGA-E[(cRGDyK)]2 Angiogenesis PET/MR in a Porcine Model of Chronic Myocardial Infarction
Autor:
Simon Bentsen, Andreas Clemmensen, Mathias Loft, Mette Flethøj, Karina Poulsdóttir Debes, Trine Pagh Ludvigsen, Cecilie Bjørstrup Larsen, Jeppe Kirchhoff, Lisbeth Høier Olsen, Jacob Eifer Møller, Thomas Lund Andersen, Helle Hjorth Johannesen, Thomas Jespersen, Andreas Kjaer
Publikováno v:
Diagnostics, Vol 11, Iss 10, p 1807 (2021)
Angiogenesis is crucial in tissue repair and prevents scar tissue formation following an ischemic event such as myocardial infarction. The ischemia induces formation of new capillaries, which have high expression of integrin αvβ3. [68Ga]Ga-NODAGA-E
Externí odkaz:
https://doaj.org/article/2e1ec1da062c4d3f9ad3c956ff6ad923
Autor:
Esben Andreas Carlsen, Mathias Loft, Annika Loft, Dorota Czyzewska, Mikkel Andreassen, Seppo W. Langer, Ulrich Knigge, Andreas Kjaer
Publikováno v:
Journal of Nuclear Medicine. 64:252-259
Autor:
Mathias Loft, Camilla B. Johnbeck, Esben A. Carlsen, Helle H. Johannesen, Peter Oturai, Seppo W. Langer, Ulrich Knigge, Andreas Kjaer
Publikováno v:
Diagnostics, Vol 11, Iss 2, p 350 (2021)
The recent introduction of solid-state detectors in clinical positron emission tomography (PET) scanners has significantly improved image quality and spatial resolution and shortened acquisition time compared to conventional analog PET scanners. In a
Externí odkaz:
https://doaj.org/article/acab645249994e589f10d257edcf6495
Autor:
Mathias Loft, Esben A. Carlsen, Camilla B. Johnbeck, Christoffer V. Jensen, Flemming L. Andersen, Seppo W. Langer, Peter Oturai, Ulrich Knigge, Andreas Kjaer
Publikováno v:
Molecular Imaging and Biology. 24:600-611
Publikováno v:
Journal of magnetic resonance imaging : JMRIReferences.
Autor:
Esben Andreas Carlsen, Mathias Loft, Annika Loft, Anne Kiil Berthelsen, Seppo W. Langer, Ulrich Knigge, Andreas Kjaer
Publikováno v:
J Nucl Med
Carlsen, E A, Loft, M, Loft, A, Berthelsen, A K, Langer, S W, Knigge, U & Kjaer, A 2022, ' Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy ', Journal of Nuclear Medicine, vol. 63, no. 9, pp. 1371-1377 . https://doi.org/10.2967/jnumed.121.263177
Carlsen, E A, Loft, M, Loft, A, Berthelsen, A K, Langer, S W, Knigge, U & Kjaer, A 2022, ' Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy ', Journal of Nuclear Medicine, vol. 63, no. 9, pp. 1371-1377 . https://doi.org/10.2967/jnumed.121.263177
The clinical course for patients with neuroendocrine neoplasms (NENs) ranges from indolent to highly aggressive. Noninvasive tools to improve prognostication and guide decisions on treatment are warranted. Expression of urokinase plasminogen activato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6deb2377261c2df148ea296215d2e74
https://europepmc.org/articles/PMC9454472/
https://europepmc.org/articles/PMC9454472/
Autor:
Mathias Loft, Claes N. Ladefoged, Camilla B. Johnbeck, Esben A. Carlsen, Peter Oturai, Seppo W. Langer, Ulrich Knigge, Flemming L. Andersen, Andreas Kjaer
Publikováno v:
Journal of Nuclear Medicine. :264826
Publikováno v:
Journal of Magnetic Resonance Imaging. 57:1876-1877
Autor:
Ulrich Knigge, Shadfar Bahri, Johannes Czernin, Peter Iversen, Andreas Kjaer, Esben Andreas Carlsen, Christine Powell, Johanna Maffey-Steffan, Henning Grønbæk, Irene Virgolini, Sandy McEwan, Colin G. Miller, Mathias Loft, Thomas Rohban
Publikováno v:
Virgolini, I, Bahri, S, Kjaer, A, Gronbaek, H, Iversen, P, Carlsen, E A, Loft, M, Knigge, U, Maffey-Steffan, J, Powell, C, Miller, C G, Rohban, T, McEwan, S & Czernin, J 2022, ' A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68 Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors ', Journal of Nuclear Medicine, vol. 63, no. 3, pp. 376-383 . https://doi.org/10.2967/jnumed.121.261936
Virgolini, I, Bahri, S, Kjaer, A, Gronbaek, H, Iversen, P, Carlsen, E A, Loft, M, Knigge, U, Maffey-Steffan, J, Powell, C, Miller, C G, Rohban, T, McEwan, S & Czernin, J 2022, ' A randomised, factorial phase II study to determine the optimal dosing regimen for 68 Ga-satoreotide trizoxetan as an imaging agent in patients with gastroenteropancreatic neuroendocrine tumours ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 63, no. 3 . https://doi.org/10.2967/jnumed.121.261936
Virgolini, I, Bahri, S, Kjaer, A, Gronbaek, H, Iversen, P, Carlsen, E A, Loft, M, Knigge, U, Maffey-Steffan, J, Powell, C, Miller, C G, Rohban, T, McEwan, S & Czernin, J 2022, ' A randomised, factorial phase II study to determine the optimal dosing regimen for 68 Ga-satoreotide trizoxetan as an imaging agent in patients with gastroenteropancreatic neuroendocrine tumours ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 63, no. 3 . https://doi.org/10.2967/jnumed.121.261936
68Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist associated with high sensitivity and reproducibility in neuroendocrine tumour (NET) detection and localisation. However, the optimal peptide mass and radioactivity ranges for 68G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f46b7d8b3fed34544124a81cf18e8ced
https://pure.au.dk/portal/da/publications/a-randomized-factorial-phase-ii-study-to-determine-the-optimal-dosing-regimen-for-68gasatoreotide-trizoxetan-as-an-imaging-agent-in-patients-with-gastroenteropancreatic-neuroendocrine-tumors(efd7ada3-d130-4069-aa7e-652d008e0f37).html
https://pure.au.dk/portal/da/publications/a-randomized-factorial-phase-ii-study-to-determine-the-optimal-dosing-regimen-for-68gasatoreotide-trizoxetan-as-an-imaging-agent-in-patients-with-gastroenteropancreatic-neuroendocrine-tumors(efd7ada3-d130-4069-aa7e-652d008e0f37).html